Skip to main content
Have a personal or library account? Click to login
Effects of substituents on the NMR features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between NMR chemical shifts, molecular descriptors and drug-likeness parameters Cover

Effects of substituents on the NMR features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between NMR chemical shifts, molecular descriptors and drug-likeness parameters

By:   
Open Access
|Dec 2010

References

  1. P. C. Appelbaum and P. A. Hunter, The fluoroquinolone antibacterials: past, present and future perspectives,(2000) 5-15; DOI: 10.1016/S0924-8579(00)00192-8.
  2. D. C. Hooper,(Eds. D. C. Hooper and E. Rubinstein), AMS Press, Washington 2003, pp. 3-40.
  3. S. Emami, A. Shafiee and A. Foroumadi, Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria,(2006) 375-386; DOI: 10.2174/138955706776361493.
  4. K. E. Brighty and T. D. Gootz, The chemistry and biological profile of trovafloxacin,(1997) 1-14; DOI: 10.1093/jac/39.suppl_2.1.
  5. M. P. Montanari, M. Prenna, M. Mingoia, S. Ripa and P. E. Varaldo, In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones,(1998) 85-93; DOI: 10.1159/000007097.
  6. J. Vincent, R. Teng, D. K. Dalvie and H. L. Friedman, Pharmacokinetics and metabolism of single oral doses of trovafloxacin,(1998) 8S-13S; DOI: 10.1016/S0002-9610(98)00213-X.
  7. D. Scuster, C. Laggner and T. Lagner,(Ed. R. Vaz and T. Klabunde), Wiley WCH Verlag GmbH & Co. KGaA, Weinheim 2008, pp. 3-22.
  8. M. J. Liguori, M. G. Anderson, S. Bukofzer, J. McKim, J. F. Pregenzer, J. Retief, B. B. Spear and J. F. Waring, Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin,(2005) 177-186; DOI: 10.1124/jpet.105.096347.
  9. Q. Sun, R. Zhu, F. W. Foss, Jr. and T. L. Macdonald, Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system,(2007) 6682-6686; DOI: 10.1016/j.bmd.2007.10.070.
  10. Q. Sun, R. Zhu, F. W. Foss, Jr. and T. L. Macdonald, In vitro metabolism of a model cyclopropylamine to reactive intermediate: Insights into trovafloxacin-induced hepatotoxicity,(2008) 711-719; DOI: 10.1021/tx7003085.
  11. J. M. Domagala, Structure-activity and structure-side-effect relationships for the quinolone antibacterials,(1994) 685-706; DOI: 10.1093/jac/33.4.685.
  12. G. S. Tillotson, Quinolones: structure-activity relationships and future predictions,(1996) 320-324; DOI: 10.1099/00222615-44-5-320.
  13. L. Mandell and G. Tillotson, Fluoroquinolone safety: An overview evaluating safety and antimicrobial activity profiles based on molecular structure categorized adverse effects,(2002) 54-61.
  14. Y. Tsuzuki, K. Tomita, K. Shibamori, Y. Sato, S. Kashimoto and K. Chiba, Synthesis and structure-activity relationships of novel 7-substituted 1,4 dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as anti-tumor agents, part-2,(2004) 2097-2109; DOI: 10.1021/jm0304966.
  15. M. Paul, A. Gafter-Gvili, A. Fraser and L. Leibovici, The anti-cancer effects of quinolone antibiotics?,(2007) 825-831; DOI: 10.1007/s10096-007-0375-4.
  16. T. Norris and G. Ferry,, U.S. Pat. 6,114,531, 5 Sep. 2005.
  17. E. Rubinstein, History of quinolones and their side-effects,(2001) 3-8; 44-48; DOI: 10.1159/000057838.
  18. P. J. Shaw, A. M. Fullerton, M. A. Scott, P. E. Ganey and R. A. Roth, The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability,(2009) 293-300; DOI: 10.1016/j.taap.2009.01.018.
  19. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,(1997) 4-25; DOI: 10.1016/S0169-409X(00)00129-0.
  20. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates,(2002) 2615-2623; DOI: 10.1021/jm020017n.
  21. P. Ertl, B. Rohde and P. Selzer, Fast calculation of molecular polar surface area as a sum of fragent-based contributions and its application to the prediction of drug transport properties,(2000) 3714-3717; DOI: 10.1021/jm000942e.
  22. H. O. Kalinowski, S. Berger and S. Braun,, Georg Thieme Verlag, Stuttgart 1984.
  23. R. M. Silverstein, C. C. Bassler and T. C. Morrill,, 5th ed., Wiley, New York 1991.
  24. G. Fardella, P. Barbetti, I. Chiappini and G. Grandolini, Quantitative analysis of fluoroquinolones byH andF-NMR spectroscopy,(1995) 123-127; DOI: 10:1016/0378-5173(95)00038-K.
  25. A. Zieba, A. Mašlankiewicz and J. Sitkovski,H,C andN NMR spectra of ciprofloxacin,(2004) 903-904; DOI: 10.1002/mrc.1468.
DOI: https://doi.org/10.2478/v10007-010-0023-x | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English, Croatian
Page range: 237 - 254
Published on: Dec 6, 2010
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2010 Milena Takač, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.